



Supplementary Materials

1.Supplementary figure



Supplementary Figure S1: Violin plots comparing level of IgG anti-SRBD titer between males and females in CoronaVac/CoronaVac group and ChAdOx1/ChAdOx1 group

Boxplots show geometric mean and IQRs. Serum was collected at 4 weeks.

In CoronaVac/CoronaVac group, The GMT of anti-SRBD titer was (138.6 BAU/mL, 95% CI 69.5 – 276.2) in male, (102.2 BAU/mL, 95% CI 68.3 – 152.7) in female.

In ChAdOx1/ChAdOx1 group, The GMT of anti-SRBD titer was (159.4 BAU/mL, 95% CI 58.1 – 437.2) in male, (221.7 BAU/mL, 95% CI 166.5 – 295.2) in female.

There was no statistically significant difference between males and females in either the homologous CoronaVac (p-value = 0.436) or homologous ChAdOx1 (p-value = 0.209) group.

2.Supplementary table

	CoronaVac/CoronaVac		ChAdOx1/ChAdOx1	
	Male	Female	Male	Female
N	6	26	7	40
geoMean	138.6	102.2	159.3	221.7
Mean	164.3	159.0	280.8	313.3
95% CI	69.5 – 276.2	68.3 – 152.7	58.1 – 437.2	166.5 – 295.2
p-value	0.436		0.209	

Supplementary Table S1: Comparison of the anti-SRBD levels between males and females in homologous CoronaVac and ChAdOx1 group

Additionally, we compared the anti-SRBD qualitative level (BAU/mL) between males and females using the Wilcoxon rank sum test on R software. There was no statistically significant difference between males and females in either the

homologous CoronaVac (p-value = 0.436) or homologous ChAdOx1 (p-value = 0.209) group.

Adverse events (AEs)	CoronaVac/ ChAdOx1 N=155	CoronaVac/ CoronaVac N=32	ChAdOx1/ ChAdOx1 N=47	P-Value
Total AEs (%)	129 (83.26%)	18 (56%)	23 (49%)	0.02812
Systemic				
Feeling Feverish (%)	104 (67%)	1 (3%)	11 (23%)	<0.001
Headache (%)	51 (33%)	6 (19%)	5 (11%)	0.0057
Myalgia (%)	40 (25.81%)	2 (6%)	8 (17%)	0.0351
Dyspnea (%)	2 (1.29%)	0	0	1
Paresthesia (%)	1 (0.65%)	0	0	1
Rash (%)	3 (1.94%)	0	0	0.5357
Fatigue (%)	30 (19.35%)	2 (6%)	5 (11%)	0.098
Diarrhea (%)	4 (2.58%)	1 (3%)	2 (4%)	0.844
Nausea And Vomiting (%)	13 (8.39%)	4 (13%)	0	0.059
Local				
Injected Site Pain (%)	54 (35%)	8 (25%)	4 (9%)	0.0035

Supplementary Table S2: Comparison of Adverse Events in Each Vaccine Regimen after the second vaccination dose

The most common systemic AEs after the second vaccination dose within 4 weeks were feeling feverish (67.1%) in the CoronaVac- ChAdOx1 group and in the homologous ChAdOx1 group (23%) and headache (19%) in the homologous CoronaVac group

The most common local AE was injection site pain in all three groups (35.06% in the CoronaVac- ChAdOx1 group, 25% in the homologous CoronaVac group, and 9% the homologous ChAdOx1 group, respectively)